Spectrum rises on US FDA approval for Fusilev in colon cancer
This article was originally published in Scrip
Executive Summary
Shares of Spectrum Pharmaceuticals shot up 9.5% in morning trading on the news that Fusilev (levoleucovorin) in combination with 5-fluorouracil won US FDA approval as a palliative treatment for patients with advanced metastatic colorectal cancer – an approval the firm has been waiting for since being rejected in October 2009 (scripintelligence, 13 October 2009).